摘要
Trifluridine/Tipiracil Approved for Gastric or GEJ AdenocarcinomaFDA; oncology: FDA; oncologyThe FDA has approved trifluridine/tipiracil as a treatment for adult patients with metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma previously treated with at least two prior lines of chemotherapy that included a fluoropyrimidine, a platinum, either a taxane or irinotecan, and if appropriate, HER2/neu targeted therapy. The approval follows an FDA Priority Review designation and is based on data from a global, randomized, phase III TAGS trial evaluating trifluridine/tipiracil plus best supportive care (BSC) versus placebo plus BSC in patients with previously treated advanced gastric cancer or GEJ adenocarcinoma following progression or intolerance to previous lines of standard therapy. The trial met its primary and secondary endpoints demonstrating prolonged overall survival (OS) with trifluridine/tipiracil versus placebo, and a safety profile consistent with prior experience with this drug. Full results from the TAGS trial were presented at the European Society for Medical Oncology 2018 Congress with a simultaneous publication in The Lancet Oncology (2018;19(11):1437-1438). This approval expands the current indication for trifluridine/tipiracil in the U.S., where it is currently approved for the treatment of patients with metastatic colorectal cancer (mCRC) who have been previously treated with standard chemotherapy, based on results obtained in the RECOURSE trial. TAGS (TAS-102 Gastric Study) is a global, randomized, double-blind phase III study evaluating trifluridine/tipiracil (TAS-102) plus BSC versus placebo plus BSC in patients with metastatic gastric or GEJ cancer, refractory to standard treatments. The primary endpoint in the TAGS trial was OS, and the main secondary endpoint measures included progression-free survival, safety, and tolerability, as well as quality of life. The study enrolled 507 adult patients with metastatic gastric or GEJ cancer who had previously received at least two prior regimens for advanced disease and it was conducted in 17 countries and 110 sites around the world. Daratumumab Split-Dosing Regimen Approved for Multiple Myeloma The FDA has approved a split-dosing regimen for daratumumab, providing health care professionals and patients with multiple myeloma an option to split the first infusion over 2 consecutive days. The approval is based on data from the phase Ib EQUULEUS (MMY1001) clinical study, which demonstrated daratumumab pharmacokinetic concentrations were comparable at the end of weekly dosing, regardless of whether the first dose was administered as a split infusion or as a single infusion. The global, multi-arm study evaluated daratumumab in combination with various treatment regimens. Splitting the first dose of daratumumab over 2 consecutive days effectively reduced the duration of the first infusion and resulted in a similar rate and pattern of infusion reactions. Data from the study demonstrated that daratumumab concentrations were comparable at the end of weekly dosing regardless of whether the first 16 mg/kg dose was administered as a split infusion or single first infusion. The safety profile of daratumumab was comparable when administered initially as a split or single dose, and no new safety events were observed with a split first dose. This approval follows approvals in Canada and the European Union in December 2018 for the daratumumab initial infusion split-dosing regimen. Daratumumab is the first and only CD38-directed antibody to receive regulatory approval to treat multiple myeloma. In the U.S., daratumumab first received FDA approval in November 2015 as a monotherapy for patients with multiple myeloma who have received at least three prior lines of therapy, including a proteasome inhibitor (PI) and an immunomodulatory agent, or who are double refractory to a PI and an immunomodulatory agent. The treatment received additional approvals in November 2016 in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy. In June 2017, daratumumab received approval in combination with pomalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least two prior therapies, including lenalidomide and a PI. Most recently, in May 2018, daratumumab received approval in combination with bortezomib, melphalan, and prednisone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant, making it the first monoclonal antibody approved for newly diagnosed patients with this disease. Priority Review Granted for Fedratinib New Drug Application in Myelofibrosis The FDA has accepted the New Drug Application (NDA) for fedratinib and granted Priority Review. Fedratinib is a highly selective JAK2 inhibitor intended for the treatment of patients with myelofibrosis. Under the Prescription Drug User Fee Act, the FDA has set its action date as Sept. 3, 2019. The NDA for fedratinib is based on results from a randomized, placebo-controlled, phase III trial (JAKARTA) in patients with primary or secondary myelofibrosis, as well as a single-arm, open-label phase II trial (JAKARTA2) in patients with primary or secondary myelofibrosis previously exposed to ruxolitinib, the only FDA-approved treatment for the disease. Results of these two trials have been previously published in peer-reviewed journals. The FDA has also provided fedratinib Orphan Drug designation for the treatment of secondary and primary myelofibrosis. JAKARTA is a pivotal, phase III, multicenter, randomized, double-blind, placebo-controlled trial evaluating the efficacy of daily oral doses (400 mg or 500 mg) of fedratinib compared with placebo in patients with intermediate-2 or high-risk primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis with splenomegaly. The study included 289 subjects across 94 sites in 24 countries. The primary endpoint was spleen response rate, defined as the proportion of patients who had a reduction in spleen volume of at least 35 percent after six 1-month treatment cycles with an MRI or CT scan 4 weeks later. Secondary endpoints included symptom response rate, defined as the proportion of patients with a 50 percent or greater reduction in Total Symptom Score after six 1-month treatment cycles as measured by the modified Myelofibrosis Symptoms Assessment Form v2.0 diary. JAKARTA2 evaluated the efficacy of a once-daily dose of fedratinib (400 mg starting dose) in patients previously treated with ruxolitinib and with a diagnosis of intermediate-1 with symptoms, intermediate-2 or high-risk primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis. The study included 97 subjects across 40 sites in 10 countries. FDA placed a clinical hold on the fedratinib program in November 2013 after potential cases of Wernicke encephalopathy were reported among subjects (approximately 1%) in clinical trials. The FDA removed the clinical hold in August 2017. Fedratinib is an oral kinase inhibitor with activity against wild type and mutationally activated Janus Associated Kinase 2 (JAK2) and FMS-like tyrosine kinase 3 (FLT3). Fedratinib is a JAK2-selective inhibitor with higher potency for JAK2 over family members JAK1, JAK3, and TYK2. Abnormal activation of JAK2 is associated with myeloproliferative neoplasms, including myelofibrosis and polycythemia vera. In cell models expressing mutationally active JAK2 or FLT3, fedratinib reduced phosphorylation of signal transducer and activator of transcription (STAT3/5) proteins, inhibited cell proliferation, and induced apoptotic cell death. In mouse models of JAK2V617F-driven myeloproliferative disease, fedratinib blocked phosphorylation of STAT3/5, increased survival and improved disease-associated symptoms, including reduction of white blood cells, hematocrit, splenomegaly, and fibrosis. Lenalidomide Receives Priority Review for Follicular & Marginal Zone Lymphoma The FDA has granted Priority Review designation for the supplemental New Drug Application (sNDA) for lenalidomide in combination with rituximab (R2) for the treatment of patients with previously treated follicular and marginal zone lymphoma. Under the Prescription Drug User Fee Act, the FDA has set its action date as June 27, 2019. The sNDA is based on results from the randomized, double-blind, phase III AUGMENT study, which evaluated the efficacy and safety of the investigational R2 combination versus rituximab plus placebo in patients with relapsed/refractory follicular and marginal zone lymphoma. Results from the study were presented at the 2018 American Society of Hematology Annual Meeting. AUGMENT is a phase III, randomized, double-blind clinical trial evaluating the efficacy and safety of lenalidomide in combination with R2 versus rituximab plus placebo in patients with relapsed/refractory follicular and marginal zone lymphoma. The primary endpoint was progression-free survival, defined as the time from date of randomization to the first observation of disease progression or death due to any cause. Secondary endpoints included overall response rate, durable complete response rate, complete response rate, duration of response, duration of complete response, overall survival, event-free survival, and time to next anti-lymphoma therapy. Orphan Drug Designation for Etoposide Toniribate in R/R Biliary Tract Cancer The FDA has granted Orphan Drug Designation (ODD) to etoposide toniribate for the treatment of relapsed/refractory biliary tract cancer, also known as cholangiocarcinoma. Etoposide toniribate has shown encouraging data in phase II trials and this data has been key in securing the ODD. This news is in addition to the European Medicines Agency also granting orphan designation on June 4, 2014. As with the FDA, this designation allows protocol assistance, reduced fees, and 10-years marketing exclusivity in that disease after approval. It can also lead to speedier reimbursement in many EU member states. Etoposide toniribate is a novel topoisomerase II inhibitor in clinical development for the treatment of relapsed/refractory biliary tract cancer. This small molecule drug is designed to work by metabolizing into its active form through enzymes in the gastrointestinal tract that are active in cancer cells. Specifically, etoposide toniribate is hydrolyzed at the site of the tumor by carboxylesterase, an enzyme expressed by some tumors, to produce activated etoposide. Activated etoposide binds to and inhibits topoisomerase II, which is often elevated in tumors, resulting in double-strand breaks in tumor DNA. Damage to the tumor DNA induces apoptosis. Results of a randomized phase II trial of 23 patients with refractory, metastatic, unresectable biliary tract cancer who had relapsed following treatment with gemcitabine/cisplatin showed a 1-year overall survival of 44 percent with etoposide toniribate versus 11.3 percent with best supportive care (BSC). Overall, 55.6 percent of patients met the primary endpoint of disease control compared with 20.0 percent who received BSC. In the trial, etoposide toniribate was generally well-tolerated with a predictable toxicity profile. The most common drug-related adverse events were neutropenia, leukopenia, thrombocytopenia, anemia, alopecia, fatigue, and abdominal pain. Biliary tract cancer is a rare tumor with approximately 8,000 patients diagnosed in the U.S. every year and 10,571 in Europe. The FDA grants ODD status to medicines intended for the treatment, diagnosis, or prevention of rare diseases or disorders that affect fewer than 200,000 people in the U.S. Radical surgery is the only curative treatment for biliary tract cancer but, in most cases, the cancer is inoperable. Patients who fail first-line chemotherapy have limited treatment options and the standard of care is generally palliative. The 5-year survival rates for patients with biliary tract cancer are very low, approximately 15 percent. Biliary tract cancer can develop in any part of the bile duct system. Nearly two out of three people with biliary tract cancer are age 65 or older at the time of diagnosis, and the average age is 70. Risk factors for biliary tract cancer include age older than 65 years, alcohol consumption, bile duct stones, cirrhosis, diabetes, a family history of cholangiocarcinoma, inflammatory bowel disease (ulcerative colitis and Crohn's disease), obesity, and long-term infection with hepatitis B or C virus.